MED13: A Potential Drug Target and Biomarker for RNA Polymerase II Transcription

Target Name: MED13

NCBI ID: G9969

MED13

MED13: A Potential Drug Target and Biomarker for RNA Polymerase II Transcription

RNA polymerase II (RNA-II) is a key transcription factor that plays a central role in regulating gene expression during various cellular processes. MED13, also known as Mediator of RNA-II Transcription, Subunit 13 Homolog, is an essential protein that modulates the activity of RNA-II. It is a 21-kDa protein that is expressed in various cell types and is involved in the regulation of gene expression, DNA replication, and repair, and other cellular processes. The function of MED13 is crucial in the regulation of cellular processes, and its dysfunction has been implicated in various diseases. Therefore, targeting MED13 may provide new insights into the development of therapeutic approaches for these diseases.

Diseases and Their Implications for MED13

MED13 is involved in various cellular processes that are crucial for the regulation of gene expression. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Cancer

MED13 has been shown to play a crucial role in the regulation of gene expression in cancer cells. It has been shown to promote the progression of cancer by inhibiting the negative effects of DNA replication and repair processes. Additionally, MED13 has been shown to promote the formation of cancer-initiating cell populations, and it has been shown to contribute to the development of resistance to chemotherapy in cancer cells.

Neurodegenerative Diseases

MED13 has also been implicated in the regulation of gene expression in neurodegenerative diseases. It has been shown to contribute to the development of neurodegenerative diseases by modulating the regulation of cellular processes that are crucial for the maintenance of cellular health. Additionally, MED13 has been shown to contribute to the progression of neurodegenerative diseases by modulating the negative effects of cellular processes that are necessary for the survival of neurons.

Developmental Disorders

MED13 has also been implicated in the regulation of gene expression in developmental disorders. It has been shown to contribute to the development of developmental disorders by modulating the regulation of cellular processes that are crucial for the normal development of tissues and organs. Additionally, MED13 has been shown to contribute to the progression of developmental disorders by modulating the negative effects of cellular processes that are necessary for the development and maintenance of tissues and organs.

MED13 as a Potential Drug Target

The function of MED13 is crucial in the regulation of cellular processes, and its dysfunction has been implicated in various diseases. Therefore, targeting MED13 may provide new insights into the development of therapeutic approaches for these diseases.

Targeting MED13

Several studies have shown that targeting MED13 may be a promising strategy for the development of therapeutic approaches for various diseases.

Anti-Cancer Therapies

Targeting MED13 may be an effective strategy for the development of anti-cancer therapies. Its dysfunction in cancer cells has been shown to contribute to the progression of cancer, and targeting MED13 may provide new insights into the development of therapeutic approaches that can inhibit its function.

Neurodegenerative Diseases

Targeting MED13 may also be an effective strategy for the development of neurodegenerative diseases. Its dysfunction in these diseases has been shown to contribute to the progression of these diseases, and targeting MED13 may provide new insights into the development of therapeutic approaches that can inhibit its function.

Developmental Disorders

Targeting MED13 may also be an effective strategy for the development of developmental disorders. Its dysfunction in these diseases has been shown to contribute to their progression, and targeting MED13 may provide new insights into the development of therapeutic approaches that can inhibit its function.

Conclusion

MED13 is a protein that is involved in the regulation of gene expression in various cellular processes. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting MED13 may provide new insights into the development of therapeutic approaches for these diseases.

Protein Name: Mediator Complex Subunit 13

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors

The "MED13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets